Arbor, Vol 191, No 773 (2015)

Cáncer y fertilidad


https://doi.org/10.3989/arbor.2015.773n3009

Begoña Bermejo
Hospital Clínico Universitario de Valencia, España

Blanca Navarro
Hospital Clínico Universitario de Valencia, España

Ana Lluch
Hospital Clínico Universitario de Valencia, España

Resumen


Los cambios sociológicos de las últimas décadas han llevado a que el inicio de la maternidad se retrase de forma considerable. Por otra parte, el diagnóstico temprano de algunos cánceres como el de mama o el de cérvix y el progreso en los tratamientos oncológicos han conseguido tasas de curación muy favorables. Todo ello lleva a que la mujer, que sobrevive cada vez más a esta enfermedad, desee completar su deseo genésico que se va a ver mermado muchas veces por los tratamientos recibidos. Tener hijos es parte importante de la vida de muchas personas, y los médicos (oncólogos, cirujanos, ginecólogos, etc.) deben informar adecuadamente al paciente sobre los riesgos que su proceso conlleva sobre la fertilidad y conocer y ofrecer las diferentes opciones de preservarla. Durante este artículo nos ceñiremos a hablar de la fertilidad en la mujer, cómo se afecta, y cómo protegerla.

Palabras clave


criopreservación; estimulación ovárica; quimioprofilaxis; transposición ovárica

Texto completo:


HTML PDF XML

Referencias


Blumenfeld, Z. (2007). How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist, 12, 9, pp. 1044-1054. http://dx.doi.org/10.1634/theoncologist.12-9-1044 PMid:17914074

Callejo, J., Salvador, C., Gonzalez-Nunez, S., Almeida, L., Rodriguez, L., Marques, L. et al. (2013). Live birth in a woman without ovaries after autograft of frozen-thawed ovarian tissue combined with growth factors. Journal of Ovarian Research, 6, 1, pp. 33. http://dx.doi.org/10.1186/1757-2215-6-33 PMid:23647552 PMCid:PMC3674930

Cobo, A., Domingo, J., Perez, S., Crespo, J., Remohi, J. y Pellicer, A. (2008). Vitrification: an effective new approach to oocyte banking and preserving fertility in cancer patients. Clinical and Translational Oncology, 10, 5, pp. 268-273. http://dx.doi.org/10.1007/s12094-008-0196-7

Cobo, A., Garcia-Velasco, J. A., Domingo, J., Remohi, J. y Pellicer, A. (2013). Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients? Fertility and Sterility, 99, 6, pp. 1485-1495.

Del Mastro, L., Boni, L., Michelotti, A., Gamucci, T., Olmeo, N., Gori, S. et al. (2011). Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. Journal of the American Association, 306, 3, pp. 269-276. http://dx.doi.org/10.1001/jama.2011.991

Donnez, J., Dolmans, M. M., Pellicer, A., Diaz-Garcia, C., Sanchez Serrano, M., Schmidt, K. T. et al. (2013). Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation. Fertility and Sterility, 99, 6, pp. 1503-1513. http://dx.doi.org/10.1016/j.fertnstert.2013.03.030 PMid:23635349

Hickey, M., Peate, M., Saunders, C. M. y Friedlander, M. (2009). Breast cancer in young women and its impact on reproductive function. Human Reproduction Update, 15, 3, pp. 323-339. http://dx.doi.org/10.1093/humupd/dmn064 PMid:19174449 PMCid:PMC2667113

Kishk, E. A. y Mohammed Ali, M. H. (2013). Effect of a gonadotropin-releasing hormone analogue on cyclophosphamide-induced ovarian toxicity in adult mice. Archives of Gynecology and Obstetrics, 287, 5, pp. 1023-1029. http://dx.doi.org/10.1007/s00404-012-2658-y PMid:23224696

Lee, S. J., Schover, L. R., Partridge, A. H., Patrizio, P., Wallace, W. H., Hagerty, K. et al. (2006). American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. Journal of Clinical Oncology, 24, 18, pp. 2917-2931. http://dx.doi.org/10.1200/JCO.2006.06.5888 PMid:16651642

Loren, A. W., Mangu, P. B., Beck, L. N., Brennan, L., Magdalinski, A. J., Partridge, A. H. et al. (2013). Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology, 31, 19, pp. 2500-2510. http://dx.doi.org/10.1200/JCO.2013.49.2678 PMid:23715580

Meirow, D., Hardan, I., Dor, J., Fridman, E., Elizur, S., Ra'anani, H. et al. (2008). Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. Human Reproduction, 23, 5, pp. 1007-1013. http://dx.doi.org/10.1093/humrep/den055 PMid:18344563

Peccatori, F. A., Azim, H. A., Jr., Orecchia, R., Hoekstra, H. J., Pavlidis, N., Kesic, V. et al. (2013). Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 24 Suppl 6, pp. vi160-170. http://dx.doi.org/10.1093/annonc/mdt199 PMid:23813932

Reddy, J. y Oktay, K. (2012). Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. Fertility and Sterility, 98, 6, pp. 1363-1369. http://dx.doi.org/10.1016/j.fertnstert.2012.09.022 PMid:23058686

Ruddy, K. J., Guo, H., Barry, W., Dang, C. T., Yardley, D. A., Moy, B. et al. (2015). Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Research and Treatment, 151, 3, pp. 589-596. http://dx.doi.org/10.1007/s10549-015-3426-z PMid:25981899

Sanchez-Serrano, M., Novella-Maestre, E., Rosello-Sastre, E., Camarasa, N., Teruel, J. y Pellicer, A. (2009). Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation. Human Reproduction, 24, 9, pp. 2238-2243. http://dx.doi.org/10.1093/humrep/dep196 PMid:19491203

Siegel, R., Ma, J., Zou, Z. y Jemal, A. (2014). Cancer statistics, 2014. CA A Cancer Journal for Clinicians, 64, 1, pp. 9-29. http://dx.doi.org/10.3322/caac.21208 PMid:24399786

Sonmezer, M. y Oktay, K. (2006). Fertility preservation in young women undergoing breast cancer therapy. Oncologist, 11, 5, pp. 422-434. http://dx.doi.org/10.1634/theoncologist.11-5-422 PMid:16720842

Zamah, A. M., Mauro, M. J., Druker, B. J., Oktay, K., Egorin, M. J., Cedars, M. I. et al. (2011). Will imatinib compromise reproductive capacity? Oncologist, 16, 10, pp. 1422-1427.




Copyright (c) 2015 Consejo Superior de Investigaciones Científicas (CSIC)

Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento 4.0 Internacional.

Contacte con la revista arbor@csic.es

Soporte técnico soporte.tecnico.revistas@csic.es